Marco Meglio

In a Health Union survey of more than 400 patients, those with focal seizures were more likely to say they’ve experienced discrimination, isolation, and reduced productivity at work compared with those without.

The risk of 5-year ipsilateral recurrent stroke was 14.3% for those with Symptomatic Carotid Atheroma Inflammation Lumen-Stenosis scores of at least 3 compared with 2.6% for those with low-risk category scores.

Hypoperfusion index was able to estimate the rate of core progression in patients with stroke who had otherwise unclassified progression by reperfusion trial core time criteria.

In cases with reported behavioral variant AD, investigators observed AD-like pattern with relative frontal sparing and a relatively more behavioral variant frontotemporal dementia-like pattern with both posterior and anterior involvement.

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided an inside look at the ways MR fingerprinting can provide real-time clinical benefit for physicians and patient care.

Habits of moderate-to-vigorous exercise were preferentially associated with slower decline of postural and gait stability, and work-related activity levels were primarily associated with slower deterioration of processing speed.

Those who had crossovers of ALS and frontotemporal dementia had structural and functional resemblance to the patterns of damage of those with only behavioral variant frontotemporal dementia.

Becky Tilahun, PhD, a clinical psychologist at Cleveland Clinic, offered insight into a recent study she and colleagues conducted exploring CBT-informed psychotherapy for patients with psychogenic nonepileptic seizures

The research also identified small subcortical cerebral amyloid angiopathy-associated acute ischemic stroke lesions as risk factors for death in these patients.

Regions typically affected by Alzheimer disease-related neurodegeneration were similarly protected by the carriership of at least 1 ε2 allele, regardless of their load.

The combination of diagnostic tests lateralized MRI-negative temporal lobe epilepsy with greater than 80% accuracy, offering considerable gain over visual radiologic assessment.

The data, which included information from more than 10 million adults collected over 20 years, lend credence to a long-held theory in the field.

The authors noted that the findings indirectly support the use of highly effective disease-modifying treatments from the early stages of disease in those with pediatric-onset MS, even in the absence of persistent physical disability.

Only 30% of the observed cohort of more than 150 children had their hypertonia type specified as spasticity and/or dystonia by age 5 years, highlighting a need for additional education efforts.

Although both are dopamine reuptake inhibitors, those on MAO-B inhibitors demonstrated greater mean PDQ-39 mobility scores and EuroQol 5-dimension 3-level scores over a median of 4.5 years.

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center discussed why MR fingerprinting holds significant clinical potential in epilepsy and epilepsy-related disorders.

The noninvasive vagus nerve stimulation device showed results consistent with what had been previously observed in the literature, with a particular benefit observed for those who have migraine with aura.

Darcy Krueger, MD, PhD, director, Tuberous Sclerosis Clinic, Cincinnati Children’s, discussed the idea behind swiftly treating tuberous sclerosis at infant stages using targeted therapeutic approaches.

Daridorexant, which will be marketed as Quviviq, will be available later this year after being scheduled by the US Drug Enforcement Administration.

The association of feelings of worse performance depended on age, with a higher frequency of amyloid positivity at older ages and a lower frequency at lower ages.

This now-validated tool showed an ability to accurately identify focal seizure-onset zone, which may help epilepsy centers when faced with the challenge of whether a patient should undergo implantation.

Patients treated with valbenazine demonstrated favorable outcomes on all secondary outcomes over placebo, as well showed no new safety signals.

The Jazz Pharmaceuticals’ product, which was FDA approved in August 2021, demonstrated clinically meaningful differences compared with placebo on several secondary end points, including impression of change scales and various and questionnaires.

Six months post-surgery, patients on either general anesthesia or local anesthesia demonstrated similar motor improvements, indicated by scores on the MDS-UPDRS, as well as similar safety findings.

Anne-Maree Kelly, MD, director, Joseph Epstein Center for Emergency Medicine Research, detailed the complexities of presenting migraine in the emergency department and why consensus international/national guidelines tailorable to the capabilities of institutions is necessary.

DMT discontinuation resulted with new disability worsening and/or progression in previously stable patients with relapsing-remitting MS and particularly in patients with previously stable secondary progressive MS.

The research assistant professor at the Buffalo Neuroimaging Analysis Center discussed the importance of continued research on how patients with multiple sclerosis experience cognitive decline as they age.

Favorable outcome, defined as modified Rankin Scores of 0-2, was achieved in patients presenting with ASPECTS of 2-5 regardless of treatment with mechanical thrombectomy in the early or extended windows.

The study authors concluded that while there are differences in survival between specific ASMs, lamotrigine and levetiracetam appear to be reasonable first-line treatment options for patients with poststroke epilepsy.

These news stories in stroke and cerebrovascular disease were top of mind in the conversations in the field and were often included in NeurologyLive®’s coverage.